Sponsored by Novartis Social Business
Marriott - Imperial A
Monday, November 14, 2016 7:15 p.m. – 9 p.m.

Novartis has a wealth of experience in tackling infectious diseases through the Malaria Initiative business and is also leading in operational innovation in social business models to target non-communicable diseases (NCDs) with the launch of the Novartis Access business for NCD medicines in low-income countries. This session is intended to cover themes of Access to Medicines by applying learnings from Malaria to the rising tide of NCDs. The panelists will discuss how the progress in the fight against Malaria contributes to higher life expectancy and the rise of NCDs, the policy and operational implications of addressing the dual burden of diseases, how learning from impact measurement from infectious diseases can inform M&E for future Access initiatives for chronic diseases, and what is the vision to lead the pharmaceutical industry in Sustainable Development Goals era.

CHAIR
Richard G. Marlink
Director, Rutgers Global Health Institute, Founding Henry Rutgers Professor of Global Health, Rutgers Biomedical Health Sciences (RBHS), New Brunswick, NJ, United States

PROGRESS IN MALARIA CONTROL AND ELIMINATION AND THE RISE OF NON-COMMUNICABLE DISEASES
Charles Nelson
Chief Executive, Malaria Consortium, London, United Kingdom

EVALUATING THE IMPACT OF ACCESS TO MEDICINES PROGRAMS
Peter Rockers
Assistant Professor, Global Health, Boston University School of Public Health, Boston, MA, United States

MINISTRY OF HEALTH PERSPECTIVE ON POLICY AND OPERATIONAL IMPLICATIONS WHEN ADDRESSING DUAL DISEASE BURDEN
Marie Aimoe Muhimpundu
Medical Epidemiologist, NCD Unit, Rwanda Biomedical Centre, Kigali, Rwanda

THE NOVARTIS VISION TO LEAD THE PHARMACEUTICAL INDUSTRY IN THE SUSTAINABLE DEVELOPMENT GOALS ERA
Harald Nusser
Global Head, Novartis Malaria Initiative and Novartis Access, Basel, Switzerland

Q&A SESSION
Moderated by Richard G. Marlink
Director, Rutgers Global Health Institute, Founding Henry Rutgers Professor of Global Health, Rutgers Biomedical Health Sciences (RBHS), New Brunswick, NJ, United States

Sponsored by Meridian Bioscience, Inc.
Marriott - Marquis D
Monday, November 14, 2016 7:15 p.m. – 9 p.m.

An overview from two key experts on the challenges and advances for diagnosing Malaria in two different settings: pre-elimination areas in developing countries and imported Malaria to developed countries. In Sub-Saharan Africa, the sub-microscopic malaria is not just for the carrier but also for the community they live in. Adults with malaria may express low/delayed symptoms that might be transmitted to the youngest in the community. This ongoing threat of submicroscopic infection calls for additional diagnostic tools needed to track the malaria reservoir. On the other hand, European cities like London, Paris and Rome are seeing malaria increase as migration rises, and the magnitude of the problem is thought to be much greater than the statistics indicate.

CHAIR
Daouda Ndiaye, PharmD, PhD
Professor of Parasitology and Mycology, University Cheikh Anta Diop, Dakar, Senegal
Carlo Severini
Senior Researcher, Department of Infectious, Parasitic and Immunomitted Diseases, Istituto Superiore di Sanità, Rome, Italy

DIAGNOSING MALARIA RESERVOIR IN PRE-ELIMINATION REGIONS
Daouda Ndiaye, PharmD, PhD
Professor of Parasitology and Mycology, University Cheikh Anta Diop, Dakar, Senegal

IMPORTED MALARIA IN EUROPE: CURRENT SITUATION AND FUTURE PROSPECTIVE
Carlo Severini
Senior Researcher, Department of Infectious, Parasitic and Immunomitted Diseases, Istituto Superiore di Sanità, Rome, Italy